Immutep Limited (NASDAQ:IMMP) jumps 36% premarket on average volume in reaction to preliminary results
from a Frankfurt, Germany-based Phase 1 clinical trial evaluating the
combination of lead candidate eftilagimod alpha and Pfizer (NYSE:PFE) and Merck KGaA’s (OTCPK:MKGAY)
PD-L1 inhibitor avelumab in 12 heavily pretreated patients with solid
tumors, primarily gastrointestinal cancers. The data were virtually
presented at ASCO.
At data cutoff, the response rate was 33%
(n=4/12), all partials, while one patient showed stable cancer, implying
a disease control rate of 42% (n=5/12). Four patients progressed and
three have yet to be assessed.
On the safety front, the combo was well-tolerated with no dose-limiting toxicities.
#ASCO20
https://seekingalpha.com/news/3578885-immutep-reports-encouraging-preliminary-data-on-lead-drug-eftilagimod-alpha
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.